IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

DESSAU-ROSSLAU, Germany, March 1, 2022 /PRNewswire/ —¬†IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses based in Germany, and¬†Exothera S.A.¬†collaborate to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing on Modified Vaccinia Ankara (MVA) virus as a first example for IDT’s broad range of vector technologies.

Exothera is a leading CDMO specializing in the industrialization of vaccine and gene therapy processes. Exothera has successfully transferred IDT Biologika’s upstream process from small to large scale in the NevoLine™ Upstream platform (Univercells Technologies).

The NevoLine platform incorporates the scale-X™ structured fixed-bed bioreactor system which offers a range of scalable options to smoothly scale viral production from R&D to commercialization. This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry. The collaboration between IDT and Exothera will demonstrate the application and increased performance of the NevoLine platform at full commercial capacity.

Comments are closed.